摘要:
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.
摘要:
The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD). [INSERT CHEMICAL STRUCTURE HERE]
摘要:
The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD). [INSERT CHEMICAL STRUCTURE HERE]
摘要翻译:本公开内容总体上涉及式I的新化合物,包括其为CGRP受体拮抗剂的药学上可接受的盐。 本公开还涉及药物组合物和使用所述化合物治疗CGRP相关病症的药物组合物和方法,所述病症包括偏头痛和其他头痛,神经源性血管舒张,神经原性炎症,热损伤,循环休克,与绝经相关的潮红,气道炎性疾病如哮喘, 和慢性阻塞性肺病(COPD)。 [插入此处的化学结构] I
摘要:
The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.